HUP0700039A2 - Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation - Google Patents

Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation

Info

Publication number
HUP0700039A2
HUP0700039A2 HU0700039A HUP0700039A HUP0700039A2 HU P0700039 A2 HUP0700039 A2 HU P0700039A2 HU 0700039 A HU0700039 A HU 0700039A HU P0700039 A HUP0700039 A HU P0700039A HU P0700039 A2 HUP0700039 A2 HU P0700039A2
Authority
HU
Hungary
Prior art keywords
medicines
preparation
cell proliferation
decreasing cell
cannabinoid drugs
Prior art date
Application number
HU0700039A
Other languages
English (en)
Inventor
Lawrence Recht
Robert B Zurier
Sumner Burstein
Original Assignee
Manhattan Pharmaceuticals
Lawrence Recht
Robert B Zurier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manhattan Pharmaceuticals, Lawrence Recht, Robert B Zurier filed Critical Manhattan Pharmaceuticals
Publication of HUP0700039A2 publication Critical patent/HUP0700039A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
HU0700039A 2000-05-17 2001-05-17 Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation HUP0700039A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
PCT/US2001/016150 WO2001087297A1 (en) 2000-05-17 2001-05-17 Cannabinoid drugs

Publications (1)

Publication Number Publication Date
HUP0700039A2 true HUP0700039A2 (en) 2007-05-02

Family

ID=22760084

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0700038A HUP0700038A2 (en) 2000-05-17 2001-05-17 Use of (3r,4r)-delta8-tetrahydrocannabinol-11-oic acids for the preparation of medicines for decreasing cell proliferation
HU0700039A HUP0700039A2 (en) 2000-05-17 2001-05-17 Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0700038A HUP0700038A2 (en) 2000-05-17 2001-05-17 Use of (3r,4r)-delta8-tetrahydrocannabinol-11-oic acids for the preparation of medicines for decreasing cell proliferation

Country Status (13)

Country Link
US (2) US6448288B1 (hu)
EP (2) EP1307188B1 (hu)
JP (2) JP2003533478A (hu)
CN (2) CN1227007C (hu)
AT (1) ATE406156T1 (hu)
AU (5) AU2001263217A1 (hu)
CA (2) CA2409005A1 (hu)
DE (1) DE60135557D1 (hu)
HU (2) HUP0700038A2 (hu)
IL (3) IL152891A0 (hu)
NZ (2) NZ523029A (hu)
RU (2) RU2272620C2 (hu)
WO (3) WO2001087297A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517194A (ja) 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
JP2007501279A (ja) * 2003-05-20 2007-01-25 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション カンナビノイド誘導体、その製造方法、および使用
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
JP2009510078A (ja) * 2005-09-29 2009-03-12 エーエムアール テクノロジー インコーポレイテッド Δ−９−テトラヒドロカンナビノールの生成法
WO2007047010A2 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
IL152891A0 (en) 2003-06-24
US20040225011A1 (en) 2004-11-11
CN1452485A (zh) 2003-10-29
EP1307186A4 (en) 2005-10-19
AU6169501A (en) 2001-11-26
CA2409005A1 (en) 2001-11-22
IL152892A0 (en) 2003-06-24
WO2001087295A1 (en) 2001-11-22
EP1307188B1 (en) 2008-08-27
CN1227007C (zh) 2005-11-16
US6914072B2 (en) 2005-07-05
IL152892A (en) 2010-06-30
RU2272620C2 (ru) 2006-03-27
NZ523029A (en) 2004-11-26
AU6468001A (en) 2001-11-26
NZ523028A (en) 2004-09-24
AU2001261695B2 (en) 2005-06-16
EP1307188A4 (en) 2005-07-06
CN1273123C (zh) 2006-09-06
US6448288B1 (en) 2002-09-10
US20020022653A1 (en) 2002-02-21
WO2001087296A1 (en) 2001-11-22
EP1307188A1 (en) 2003-05-07
CN1447685A (zh) 2003-10-08
JP2003533478A (ja) 2003-11-11
ATE406156T1 (de) 2008-09-15
JP2003533479A (ja) 2003-11-11
RU2273476C2 (ru) 2006-04-10
EP1307186A1 (en) 2003-05-07
AU2001263217A1 (en) 2001-11-26
HUP0700038A2 (en) 2007-05-02
AU2001264680B2 (en) 2006-09-14
WO2001087295A8 (en) 2003-04-10
DE60135557D1 (de) 2008-10-09
CA2408961A1 (en) 2001-11-22
WO2001087297A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
HUP0204015A3 (en) Devices for the delivery of drugs having antiprogestinic properties
IL149224A0 (en) Hydrogen-driven drug dosage form
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HK1077832A1 (en) 17a-ALKYL-17ß-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE FRODUCTION THEREOF, AND USE OF SAID 17a-ALKYL-17ß-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
HK1068812A1 (en) Drug preparations
GB0117618D0 (en) Pharmaceutical dosage form
EP1455697A4 (en) VAGINAL DRUG DELIVERY
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
GB0117619D0 (en) Pharmaceutical dosage form
PL351686A1 (en) Novel pharmaceutical
EG23937A (en) Novel pharmaceutical
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
AU2001243515A1 (en) Combination drug therapy
HK1064042A1 (en) Medicines and medicinal kits
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001291690A1 (en) Drugs for sex dysfunctions
PL351135A1 (en) Novel pharmaceutical
EG23946A (en) Novel pharmaceutical
IL158312A (en) Use of pyridoindolone derivatives for preparing anticancer medicines
AU2002308105A1 (en) Benzoaxathiepin derivatives and their use as medicines
HUP0203557A3 (en) Novel amidine derivatives, preparation and use thereof as medicines
AU2002215923A1 (en) Use of medicaments
GB9923933D0 (en) Novel pharmaceutical
GB0021927D0 (en) Use of pharmaceutical combination

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees